In Part One of this two-part series, we discussed skin physiology and anatomy as well as generalities concerning topical analgesics. This modality of therapy has lesser side effects and drug-drug interactions, and patients tolerate this form of therapy better than many oral options. Unfortunately, this modality is not used as often as it could be in chronic pain states, such as that from neuropathic pain. Part Two discusses specific therapies, local anesthetics, and other drugs, as well as how a clinician might use specific aspects of a patient's neuropathic pain presentation to help guide them in the selection of a topical agent.
INTRODUCTION
Topical agents do not have a large market share in the treatment of chronic pain. The total market for over-the-counter analgesics alone is estimated at $2.38 billion [1] . In 2007, the market for topical analgesics (TAs) was only $40 million [2] . These data suggest that these treatments are underutilized. There are a number of different potential therapies, other than diclofenac and lidocaine topical options.
Multiple different medications and mechanisms are currently being evaluated by the pharmaceutical industry.
Indeed, some of these mechanisms can be taken advantage of today, by developing a working relationship with a pharmacy that can compound TAs with multiple mechanisms and different drugs. In line with the repeated observations that TA use is generally associated with a more desirable side effect profile than orally, transdermally, parenterally, or intrathecally administered analgesics, these observations should be especially considered when developing a pain management treatment regimen for an individual patient.
Currently, only a few options are available in the market, and clinicians work in concert with compounding pharmacists to produce various compounded TAs. This is not a rare occurrence as an Internet survey of 120 physicians showed 27% of those surveyed used compounded topical agents as part of their practice [3] . The research approach of much of the compounding industry is the (n of 1) trial [4] . This is not unfamiliar to practicing clinicians who frequently ''try'' an agent in a given patient to evaluate efficacy and tolerability. This review article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
LOCAL ANESTHETIC ANALGESICS: AN OVERVIEW OF TOPICAL THERAPIES
Sodium channels are highly expressed in axons and dendrites as well as centrally [5] .
Furthermore, there are multiple channel subtypes, some of which are involved in the expression of pain. Although these transient channels appear very similar, such as voltagegated sodium channel (Na v ) 1.1-1.7, their actions are different [6] ; Na v 1.7, Na v 1.8, Na v 1.9 play roles in inflammatory pain [7] .
The role for Na v 1.3 is controversial and the channels Na v 1.6, and Na v 1.1 all warrant more in-depth investigation [8] . Local analgesic (LA) agents suppress the activity of peripheral sodium channels within sensory afferents and subsequent pain transmission; however, other mechanisms of action are still under investigation. There is decreased expression of messenger ribonucleic acid for specific sodium channel subtypes following use of LA [9, 10] .
Furthermore, LAs preferentially block hyperexcitable cells [5] . LAs have been used by topical, intravenous, and subcutaneous routes in the treatment of chronic pain for years.
Several LAs used as TAs are currently available including the lidocaine 5% patch (L5P); the eutectic mixture of LAs, 2.5% lidocaine/2.5% prilocaine (EMLA); and a lidocaine 70 mg/tetracaine 70 mg patch (LTP). Of these three agents, only the L5P is associated with an analgesic effect without anesthetizing skin, whereas EMLA or LTP creates both analgesia and anesthesia. This difference may be useful in different clinical settings, for example, venipuncture and circumcision, for which creating both analgesia and anesthesia are helpful [10] .
The use of specific TAs for the management of neuropathic pain has been supported by evidence from clinical trials and published reviews [11] [12] [13] . Among the currently available topical options, the L5P has been widely studied. The outcome of two studies assessed the tolerability and safety of 24-h use of up to four L5Ps for extended periods of time. There were no significant systemic side effects or dermal reactions, and plasma lidocaine levels remained low [14, 15] . Safety and tolerability were similar for either 12-or 24-h application [10, 14] .
LAs have also been studied in conditions not typically considered responsive, such as low back pain. For example, a multicenter, openlabel study involved 120 patients with acute (\6 weeks), subacute (\3 months), short-term chronic (3-12 months), or long-term chronic ([12 months) low back pain. During the 6-week study, a majority of patients experienced moderate or greater pain relief with four L5Ps applied to the most painful low back areas [16] .
A randomized, double-blind, placebocontrolled trial conducted in Europe evaluated the analgesic efficacy of the L5P in the treatment of ''focal'' neuropathic pain syndromes, for example, mononeuropathies and ilioinguinal neuralgia [17] . Adding the patch to other pharmacotherapeutic regimens could reduce pain and allodynia as quickly as within 8 h of application [17] . A smaller openlabel study of 16 patients with various neuropathic pain conditions, for example, complex regional pain syndrome (CRPS) or diabetic peripheral polyneuropathy (DPPN), demonstrated that the L5P provided pain relief without significant side effects in 81% of patients [18] . It is noteworthy that patients enrolled in this study, prior to the use of the L5P, had experienced suboptimal outcomes with other commonly prescribed agents. Several other noncontrolled studies using the L5P in patients with DPPN have been completed. These studies allowed patients to use as many as four L5Ps for as long as 18 h per day. Viewing these studies as a group, the majority of enrolled subjects reported pain reduction and good tolerability [19, 20 ]. An additional 3-week, single-center, open-label study of the L5P in patients with painful idiopathic sensory polyneuropathy noted significant improvements in both pain relief and quality of life [20] . In a phase IV study of 332 postherpetic neuralgia (PHN) patients using the L5P, 67% noted decreased pain intensity by the end of the first week. Further reductions were noted by the second week in more than 40% of those who had not experienced pain relief during the first study week. Overall, 70%
of enrolled patients experienced improvement [21] . In another open-label study, treatment with the L5P was compared with pregabalin for PHN. The L5P was at least as effective as pregabalin in this study. Interestingly, for patients who had not responded to either treatment alone, these agents in combination resulted in greater benefit and tolerability [22] .
Changes in PHN pain quality when using the L5P compared with placebo were evaluated in a multicenter, randomized, vehicle-controlled study of 150 patients [23] . Reduced pain symptoms, assessed using the Neuropathic Pain Scale, were more likely to occur in the L5P patients compared with placebo.
Interestingly, neuropathic pain that was deep, sharp, and burning was previously assumed to be related to mechanisms of the central, and not peripheral, nervous system; however, L5P provided relief for these sensations as well. In the discussion of the study's results, it was proposed that, given the localized primary peripheral nervous system (PNS) mechanism of action of the L5P, peripheral mechanisms might also be important for the development of other 
CYCLOOXYGENASE INHIBITORS
The mechanism of action of a topical nonsteroidal anti-inflammatory drug (NSAID) is likely related to anti-inflammatory inhibition through prostaglandin synthesis via its adenosine triphosphate-sensitive K ? channel opening property [54, 55] . However, the extent of anti-inflammatory effect is not proportional to pain relief, and other mechanisms of action might be involved [55] .
Diclofenac is available in dermal and transdermal formulations, gels, patches, creams, and lotions. Since 2007, three topical NSAIDs have been approved, including diclofenac sodium gel 1% for treating osteoarthritis (OA) pain, the diclofenac epolamine 1.3% topical patch for acute musculoskeletal pain, and the diclofenac 1.5% topical solution for OA of the knee [56] .
The use of other topical NSAIDs has been studied most notably outside of the United States. For example, a topical ketoprofen patch (100 mg) was found superior to placebo in reducing pain following 7 days of treatment in a randomized, placebo-controlled study of 163 patients with ankle sprains [57] . In a separate study, patients with tendonitis were randomized in a double-blind, placebocontrolled study. The NSAID group fared better than placebo with only minor skin irritation and was well tolerated [58] . A small controlled study showed that a topical mixture of aspirin and diethyl ether was a significantly more effective analgesic than placebo in patients with acute herpes zoster and with PHN [59] . The use of TAs for the treatment of OA has also been studied and multiple recent reviews have been published recently [16, [60] [61] [62] . A diclofenac patch preparation demonstrated safety and efficacy in a randomized, double-blind controlled study in patients with chronic knee OA pain [63] . A randomized controlled study comparing topical diclofenac solution to oral diclofenac for knee OA concluded that the solution produced symptom relief equivalent to oral diclofenac, but with decreased incidence of gastrointestinal complaints [64] .
Gastrointestinal side effects from oral diclofenac included abdominal pain, nausea, dyspepsia, and diarrhea [64] . A recently published long-term study with the same topical solution confirmed the safety parameters of the study [65] . In a pooled safety analysis of two large studies (one of which was [64] ) comparing oral diclofenac with a topical diclofenac solution for the treatment of OA, although the rate of adverse events (AEs) between the two preparations was similar, patients treated with the oral diclofenac experienced more gastrointestinal (39.0% vs 25.4%, P\0.0001) and cardiovascular (3.5% vs 1.5%, P = 0.055) AEs [66] . The oral diclofenac in the two studies was also associated with significantly greater increases in liver enzymes and creatinine, as well as greater decreases in creatinine clearance and hemoglobin (P\0.001 for all). By contrast, patients receiving the topical solution had more dry skin at the application site (24.1% vs 1.9%, P\0.0001) [66] . Diclofenac solution was compared with oral diclofenac in a parallel-arm study of individuals with temporomandibular joint pain. Although there was no significant difference in analgesic benefit, there were significantly fewer gastrointestinal side effects with the topical solution [67] . Two other trials demonstrated the efficacy of topical 1.16% diclofenac gel and topical solution compared with placebo, showing benefit and safety [68, 69] . In one metaanalysis, there was evidence to suggest that topical NSAIDs were more effective than placebo [70] . However, the authors concluded that available evidence indicated that topical NSAIDs were inferior to oral NSAIDs during the first week of treatment [70] . A separate metaanalysis examined the use of topical NSAIDs for chronic musculoskeletal pain and concluded they are effective and safe [71] . Interestingly, paraffin baths have been used to alleviate pain from OA and to improve function. When TAs were added to the paraffin bath, at least in one study using essential oils, this increased the analgesic effect of the bath [72] . A randomized controlled study of a diclofenac patch in 120 individuals experiencing acute pain after ''blunt'' injury demonstrated that the diclofenac patch was well tolerated and reduced pain intensity more than placebo [73] . Two studies, one noncontrolled and the other a multicenter, randomized, controlled study, noted that a diclofenac patch was found to be well tolerated and effective, with 60% pain relief in acute sports injuries [74, 75] . In another controlled study, topical ibuprofen cream was found to be superior in reducing pain from acute ankle sprains [76] . In a controlled study of ketoprofen gel in acute soft tissue pain, the gel was more effective than placebo in providing pain relief [77] . A topical formulation of ibuprofen 5% gel was examined in a 7-day placebo-controlled study in patients with soft tissue pain. Patients received either the ibuprofen 5% gel or placebo gel. A significant difference (P\0.001) in pain reduction and improved physical activity was experienced in the study group [78] . A second similar study completed by the same investigators demonstrated similar results [60] . A further study using topical flurbiprofen for soft tissue pain reported greater pain reduction than oral diclofenac and fewer adverse effects [79] . This study is one of very few that actually compared a topical NSAID to an oral agent.
A meta-analysis reviewed the limited data and concluded that the effects of topically applied rubefacients containing salicylates resulted in moderate to poor efficacy. The authors emphasized that efficacy estimates were currently unreliable because of poorly designed clinical trials [80] . A randomized, controlled study with the topical NSAID eltenac examined its effect compared with oral diclofenac and placebo in 290 patients with knee OA. The TA, compared with placebo, showed greater safety and efficacy [81] . Each active treatment, in patients with severe symptoms, resulted in superior analgesia compared with placebo, with the incidence of gastrointestinal side effects lower in the eltenac gel group compared with that of the oral diclofenac group [81] . A double-blind placebocontrolled study in patients with OA of the knee demonstrated efficacy with a topical diclofenac patch in reducing pain [82] .
In conclusion, the 2007 Cochrane Database review suggested that topical NSAIDs can provide good levels of pain relief without significant systemic adverse effects associated with oral NSAIDs, for the treatment of acute musculoskeletal pain [78] .
TOPICAL OPIOIDS
Although a large variety of topical transdermal opioid preparations exist (many for the treatment of chronic cancer pain), because these are absorbed systemically (unlike topical opioid preparations that are not, or not designed to be, absorbed systemically), they will not be discussed here. Instead we focus solely on topical opioid preparations. A published case series reported the potential benefit of ''topical'' morphine in the management of chronic OA-related pain; however, the report emphasized that morphine and/or its metabolites were identifiable in the urine of treated patients, thus calling into question how truly ''topical'' this preparation was, given its systemic effects [83] . Preclinical studies indicate that opioids such as morphine, methadone, and buprenorphine can be analgesics when administered topically [84] [85] [86] . Morphine gel can be effective in relieving pain of skin ulcers and calciphylaxis in dialysis patients [87, 88] 
OTHER DRUG OPTIONS AND COMBINATIONS
Topical clonidine 0.1% gel significantly decreases pain in patients with DPPN who had previously experienced burning pain from capsaicin applied to the affected skin, an interesting finding in light of the discussion in Sect. ''Potential predictors of response to neuropathic pain treatments'', below [92] . It was found to be safe, with application site reactions only observed in the placebo group [92] . By contrast, intrathecal clonidine for the treatment of chronic pain typically results in hypotension [93] . Topical clonidine can also relieve hyperalgesia in patients suffering from sympathetically maintained pain [94] .
Amitriptyline and doxepin are known to have multiple mechanisms, including local anesthetic properties, and these drugs may be analgesic when used topically. Notably, doxepin is currently available as a cream for the symptomatic treatment of pruritus [95] . The results of a novel study comparing the painreducing effect of a topical preparation containing 3.3% doxepin alone or a topical preparation containing 3.3% doxepin combined with 0.075% capsaicin to placebo in patients with a variety of chronic neuropathic pain problems indicated that each treatment provided similar pain-reducing effects and both were superior to placebo [95] . Although two clinical trials of amitriptyline, ketamine, and the combination failed to show efficacy in patients with neuropathic pain, these have been used empirically [96, 97] . Observations of effectiveness of topical amitriptyline alone or in combination with other drugs, such as ketamine, have been reported mostly in the management of painful disorders, for example, proctodynia [98] . Two open-label trials, the first involving 28 patients with neuropathic pain who were treated with the combination amitriptyline 2%/ketamine 1%, showed pain reduction and encouraging results [96, 99] . Amitriptyline and ketamine topical combinations have also been used in patients suffering from cancer pain, such as in a study
showing that a topical amitriptyline, ketamine, and lidocaine preparation was safe and effective in alleviating neuropathic pain caused by radiation dermatitis [100] . Noncontrolled trials evaluating the use of topical ketamine, one in patients with PHN and one in patients with CRPS type 1 have each concluded that topical ketamine may be effective; however, serum ketamine levels were not measured in either study [101] . This would be instructive to know given the difference in side effects ketamine has been shown to have between topical and oral formulations. For example, topical ketamine at 50 mg/mL was shown to not elicit any local or systemic side effects [102] , whereas intravenous ketamine for use in chronic non-cancer pain has been shown to involve a number of undesirable side effects that can limit its use, such as tachycardia, intracranial hypertension, vivid dreams and hallucinations, and the potential for urinary tract toxicity [103] . The results of an open-label, enriched, enrollment study followed by a randomization to placebo-controlled arms using either 4% amitriptyline/2% ketamine cream, 2% amitriptyline/1% ketamine cream, or placebo for patients with PHN demonstrated that higher concentrations of study drug yielded the lowest daily pain intensity compared with the lower concentration or placebo [104] . Plasma levels of either drug were detected in fewer than 10% of study patients. Topical ketamine has also been shown to be effective for mucositis pain in a patient with squamous carcinoma of the tongue undergoing radiation therapy [105] . Baclofen appears to have peripheral analgesic properties. Although a GABAergic agent orally, its hypothesized topical mechanism of action may be related to its K ? channel opening property [106] . Topical baclofen has been used empirically in combination with amitriptyline for vulvodynia [107] , and has been studied as a single agent for chemotherapy-induced painful neuropathy [108] . Topical gabapentin has been empirically used as a single agent or in combination with amitriptyline and other drugs for neuropathic pain, with a retrospective study suggesting benefit of topical gabapentin for vulvodynia [109] .
Botulinum toxin type A is an oral poison, which means that the molecule must have an efficient mechanism of endocytosis to penetrate and cross not only axon terminals but also epithelial cells. It is a zinc metalloendoprotease that cleaves the SNAP-25 protein required for synaptic vesicle fusion to release transmitters. It has been approved for the treatment of chronic migraine. When injected intradermally, a LA effect for peripheral neuropathic pain was reported in a small randomized clinical trial [110] .
Dimethyl sulfoxide (DMSO) is a powerful antioxidant. Antioxidants can prevent or reduce reactive oxygen species-induced cell damage and other free radicals known to promote a neuroinflammatory cascade that, in some instances, may play a role in the genesis of chronic pain disorders, such as CRPS. When used at the concentration of 50% in a cream base, DSMO appears to be beneficial for CRPS [111] [112] [113] . Palmitoylethanolamide (PEA) is an endogenous lipid-specifically, a fatty acid ethanolamide. PEA is an agonist of the peroxisome proliferator-activated receptor-a and has been found to possess antiinflammatory and anti-nociceptive effects [114] . In addition, PEA may inhibit the enzyme that catalyzes the endocannabinoid anandamide. PEA is available in Europe as an oral nutraceutical. Some dermatologic creams for atopic dermatitis contain PEA. It has empirically been used as a topical treatment for neuropathic pain [115] . There is one report that suggests that the topical application of geranium oil may provide temporary relief from PHN [116] .
The analgesic effect of menthol, an ingredient common to many over-the-counter analgesic preparations, was hypothesized to be the result of activation of j-opioid receptors [117] . Burn pain has been reported to be treated effectively with a topical loperamide preparation [118] . Two randomized controlled studies-one involving postoperative pain (diclofenac patch) and one involving wound pain treatment (capsicum plaster topically applied at acupuncture sites)-have been published as well [119, 120] .
An open-label study using a 0.25% capsaicin topical agent in a lidocaine vehicle in 25 DPPN patients and seven PHN patients demonstrated pain relief in a majority of patients [121] . In a noncontrolled study of 23 patients with acute migraine headache, a topically applied 0.1% capsaicin gel was helpful in reducing mild or moderate pain [122] . In a randomized, doubleblind study assessing 154 patients with chronic pain due to lateral epicondylitis, topical glyceryl trinitrate (0.72 mg/day), compared with placebo, was found to provide statistically significant greater pain relief after 8 weeks [123] . In a study of 52 patients with chronic pain due to a chronic Achilles tendinopathy, patients who had been treated with topical glyceryl trinitrate for 6 months were more likely 3 years after treatment ended to have less pain and more function than those who had been treated with placebo [124] . Published reports of the use of topical phenytoin in the treatment of pain due to superficial burns or chronic leg ulcers are noted as well [125, 126] .
The use of topical ''essential oxygen oil'' was reviewed in a 2010 paper [127] . This essential oil is a hyperoxygenated, peroxidized, triglyceroloxyester-rich oil. Although the published studies using this approach were open label or case reports and series, 100% of the patients felt that their pain was dramatically reduced.
A randomized controlled study of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for knee OA showed a significant pain reduction in the treatment group compared with the placebo group [128] .
An interesting study using a homeopathic gel compared with piroxicam gel in 184 patients with OA found that ''the homeopathic gel was at least as effective and as well tolerated as the NSAID gel'' [129] . A Cochrane review from 2006 evaluating herbal therapies for low back pain found ''three low quality trials on Capsicum Frutescens (Cayenne)'' used as TAs, finding, ''moderate evidence that Capsicum Frutescens produced more favorable results than placebo'' [130] . Table 1 lists topical non-LAs.
POTENTIAL PREDICTORS OF RESPONSE TO NEUROPATHIC PAIN TREATMENTS
Neuropathic pain is accompanied by somatosensory signs, which include contributions from peripheral and CNS structures [131] . As has been discussed in previous sections of this two-part series, 
CONCLUSION
Of great interest is the recent observation that although a TA's primary mechanism of action may be locally within the PNS, effects can be detected in the CNS using functional neuroimaging [138] . 
